Given the current paucity of effective therapeutics for KRAS mutation-positive NSCLC, these observations support the evaluation of L-NAME or perhaps other NOS inhibitors for the treatment of this disease. This evidence concerns the gene KRAS and non-small cell lung carcinoma.